Andere Sprachen Aditxt, Inc.

Aktien

A3ETCJ

US0070256047

ADTX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 15.05.2024			% 5 Tage	% 1. Jan.
2,05 ^USD	-6,82 %		-2,38 %	-69,08 %

16.04.	Aditxt, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
02.01.	Wall Street eröffnet 2024 angesichts steigender Ölpreise und vor den Daten zum verarbeitenden Gewerbe und zum Baugewerbe schwächer	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules	06.05.
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules	03.05.
Aditxt, Inc. announced that it expects to receive $4.2 million in funding	03.05.
Aditxt, Inc. announced that it expects to receive $150 million in funding	02.05.
Aditxt, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16.04.
Appili Therapeutics Signs Definitive Agreement to be acquired by Aditxt, Inc.	03.04.
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense	03.04.
Appili Therapeutics To be Acquired by Aditxt, Inc.	02.04.
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)	02.04.
Evofem Biosciences - For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy	08.03.
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy	07.03.
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023	01.02.
Aditxt, Inc. Acquires Proprietary Electroencephalography Brain Monitoring Technologies and Devices, Including NeuroCap and NeuroEEG for Telehealth and Tele-neurology Applications	31.01.
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications	30.01.
Aditxt, Inc.'s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.'s Proprietary Mitomic Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million	09.01.
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules	08.01.
Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million	08.01.
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules	05.01.
Aditxt, Inc. announced that it has received $6.000003 million in funding	04.01.
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders Equity Requirement	03.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Aditxt, Inc.

Aktien

A3ETCJ

US0070256047

ADTX

Andere Sprachen

Filter